Mei Teng Loh

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

Shweta Urva, Tamer Coşkun, Mei Teng Loh et al. · The Lancet · 2022 · 180 citations

Glucagon Receptor Agonist, G Protein-coupled Receptor, Medicine +6

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trial

David S. Small, Christopher D. Payne, Prajakti A. Kothare et al. · Clinical Therapeutics · 2010 · 47 citations

Pharmacological Study, White Volunteers, Pharmacology +6

The novel <scp>GIP</scp> , <scp>GLP</scp> ‐1 and glucagon receptor agonist retatrutide delays gastric emptying

Shweta Urva, Libbey S. O′Farrell, Yu Du et al. · Diabetes Obesity and Metabolism · 2023 · 22 citations · Full text

Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus <scp>Humalog®</scp> in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study

Christof Kazda, Jennifer Leohr, Rong Liu et al. · Diabetes Obesity and Metabolism · 2021 · 15 citations · Full text

Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus <scp>H</scp> umalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early‐phase study

Jennifer Leohr, Christof Kazda, Rong Liu et al. · Diabetes Obesity and Metabolism · 2021 · 12 citations · Full text